Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

-- THE-630 demonstrates encouraging safety profile through Cohort 6 , supportive of continued dose escalation --
-- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both... | May 25, 2023

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Philadelphia ,Pennsylvania ,Josh Rappaport ,Christen Baglaneas ,Tim Clackson ,Suzanne George ,David Kerstein ,Clinical Development Plan ,Corporate Communications Investor Relations ,Dana Farber Cancer Institute ,Theseus Pharmaceuticals ,Exchange Commission ,Theseus Pharmaceuticals Inc ,Sarcoma Center ,Nasdaq ,Predictive Resistance Assay ,Chief Executive Officer ,Associate Division Chief ,Chief Medical Officer ,Trial Background ,Clinical Development ,Theseu Form ,Quarterly Reports ,Corporate Communications ,Nc Stock Exchange ,News ,Information ,Press Release ,Emonstrates ,Ncouraging ,Safety ,Profile ,Through ,Cohort , ,Supportive ,F ,Ontinued ,Nose ,Escalation ,Reductions ,Bserved ,N ,Ctdna ,Allele ,Fractions ,Or Thrx Us88369m1018 ,